INTRODUCTION
Most human cancers have an abnormal chromosome content, a condition known as aneuploidy. However, the molecular defects underlying the development of aneuploidy and its role in tumorigenesis remain poorly understood (Michor et al., 2005) . Deciphering the molecular networks that regulate the proper segregation of chromosomes in mitosis is essential to understanding the mechanisms that can cause chromosomal instability and their role in cancer development. In Saccharomyces cerevisiae, more than 100 genes are known to cause chromosomal instability when defective (Kolodner et al., 2002; Nasmyth, 2002) . These genes function in a wide variety of mitotic processes, including chromosome condensation, sister chromatid cohesion, kinetochore assembly, spindle formation, and spindle assembly checkpoint control. Even more genes are expected to contribute to chromosomal stability in humans, but only a limited number have been identified to date (Michor et al., 2005) .
Several proteins that mediate transport of macromolecules into and out of the nucleus through nuclear pores have recently been implicated in mitosis. One of these proteins is RanBP2 (or Nup358), a very large multidomain nuclear pore complex protein that exerts SUMO E3 ligase activity in vitro (Matunis and Pickart, 2005; Pichler et al., 2002; Wu et al., 1995) . In interphase cells, RanBP2 is localized at the cytoplasmic face of the NPC, where it forms a stable subcomplex with Ran GTPase-activating protein 1 (RanGAP1) and the SUMO E2-conjugating enzyme Ubc9. Only RanGAP1 conjugated to small ubiquitin-like modifier 1 (SUMO1) can interact with RanBP2 (Mahajan et al., 1997; Matunis et al., 1996) . Depletion of RanBP2 has no measurable effect on import of proteins into the nucleus but slightly reduces export of mRNA and NES-containing proteins from the nucleus, suggesting that RanBP2 functions as a facilitator of macromolecular export (Bernad et al., 2004; Hutten and Kehlenbach, 2006) . At the onset of mitosis when the nuclear envelope (NE) disintegrates and NPCs disassemble, RanBP2-RanGAP1-SUMO1-Ubc9 subcomplexes disperse into the mitotic cytosol and accumulate at the plus ends of free spindle microtubules and at kinetochores of chromosomes that have been captured by spindle microtubules (Joseph et al., 2002 (Joseph et al., , 2004 . Kinetochore targeting of RanBP2-RanGAP1-SUMO1-Ubc9 is dependent on the nuclear export receptor Crm1 . In HeLa and RGG cells, depletion of RanBP2 causes various mitotic abnormalities, including misalignment of chromosome in metaphase, mislocalization of several kinetochore-associated proteins, and formation of multipolar spindles (Joseph et al., 2004; Salina et al., 2003) .
The critical biological functions of the mammalian RanBP2 protein have yet to be elucidated. Furthermore, although RanBP2 has SUMO E3 ligase activity in vitro, it remains unknown whether RanBP2 acts as a SUMO-ligating enzyme in vivo. To address these issues, we bypassed the problem of embryonic lethality of RanBP2 null mice (Aslanukov et al., 2006) by generating a series of mutant mice in which the dose of RanBP2 is reduced in graded fashion. We report here that mice with low amounts of RanBP2 are viable and overtly indistinguishable from wildtype mice. We show that there is an inverse correlation between RanBP2 level of expression and chromosome number instability. The prime mitotic defect associated with RanBP2 insufficiency is formation of chromatin bridges in anaphase, an abnormality linked to impaired Topo IIa-mediated decatenation of sister chromatids at anaphase (Clarke et al., 1993) . We show that RanBP2 binds to and regulates the sumoylation and localization of Topo IIa in mitosis. We further show that mice expressing RanBP2 below a threshold level are prone to spontaneous and carcinogeninduced tumorigenesis.
RESULTS

Generation of Mutant Mice with Low Amounts of RanBP2
We created a series of mice in which expression of RanBP2 is reduced in a graded fashion from normal to zero by the use of various combinations of wild-type (RanBP2 Figure S2A ). Furthermore, NLS-mediated protein import and NES-mediated protein export were both equally efficient in RanBP2 +/+ and RanBP2 À/H MEFs as measured using established in vivo transport assays ( Figures S2B-S2E ). Collectively, these results suggest that reduction of RanBP2 protein levels to about a quarter of normal levels has no overt impact on nucleocytoplasmic trafficking. (C) Western blot analysis of MEFs isolated from mice carrying the indicated RanBP2 alleles using anti-RanBP2 antibody. Actin was used as a loading control.
RanBP2 can sumoylate RanGAP1 in vitro, but whether it does so in vivo is unclear (Pichler et al., 2002) . RanBP2 has further been proposed to protect SUMO1-modified RanGAP1 from desumoylation by SUMO isopeptidases such as SENP2 (Zhang et al., 2002) . Western blot analysis of RanBP2 +/+ and RanBP2
À/H
MEF lysates for SUMO1 showed that SUMO1-RanGAP1 levels remained constant in cells with reduced RanBP2 ( Figure S2F ). The same holds true for other SUMO1-conjugated proteins and SUMO2/3-conjugated proteins level ( Figure S2G ), suggesting that hypomorphism for the SUMO E3 ligase RanBP2 does not affect the global patterns of SUMO modification in MEFs. 
RanBP2
H/H cells that were able to progress into anaphase, 30% and 28% formed chromatin bridges, respectively ( Figures  2A-2C ). Most cells had one or two bridges, while a small fraction of cells had more than two (data not shown). These bridges resolved in telophase or during cytokinesis (Figure 2A ). The percentage of chromatin bridges was much lower in RanBP2 +/À and
+/H anaphases (16% and 12%, respectively) but still significantly higher than in RanBP2 +/+ anaphases (7%) ( Figure 2C ). In addition, a small but statistically significant increase of centrophilic chromosomes was observed in RanBP2 À/H and
H/H MEFs in comparison to RanBP2 +/+ MEFs ( Figure 2C ). There was a small increase of lagging chromosomes in these MEFs that did not reach statistical significance ( Figure 2C) . Together, the above findings suggest that anaphase-bridge formation is the main chromosome segregation defect in RanBP2-insufficient cells.
To examine whether chromatin-bridge formation caused structural chromosome damage, spectral karyotype (SKY) analysis was performed on RanBP2 À/H and RanBP2 +/+ MEFs.
Although this analysis confirmed that RanBP2 À/H cells had increased numerical chromosome instability, there was no evidence for increased breakage or fusion of chromosome arms ( Figure S3A ). Giemsa-stained metaphase spreads from splenocytes and MEFs with various levels of RanBP2 were also inspected for structural chromosomal abnormalities. Again, there was no evidence for increased chromosome breakage or end-to-end fusion in RanBP2 mutant cells, although a small but significant increase in the incidence of chromosome gaps was observed in RanBP2 H/H and RanBP2 À/H splenocytes and MEFs ( Figures S3B-S3D ). These data suggest that chromosomebridge formation causes aneuploidy in the absence of extensive structural chromosome damage. However, the possibility that MEFs with structural damage have reduced viability and thus go unnoticed cannot be excluded. Previous studies of HeLa cells have documented that depletion of RanBP2 by RNA interference perturbs mitotic spindle formation and loading of certain mitotic checkpoint proteins onto kinetochores in early mitosis (Joseph et al., 2004; Salina et al., 2003) . However, no such mitotic defects were detectable in RanBP2 hypomorphic MEFs ( Figure S4 ).
Topo IIa Targeting to Inner Centromeres in Mitosis is Dependent on RanBP2
Formation of chromatin bridges in anaphase is a distinctive feature of cells in which DNA decatenation is impaired by mutation or chemical inhibition of Topo IIa (Clarke et al., 1993) . Topo IIa is active in S phase and at the metaphase-anaphase transition, where it disentangles sister centromeres to enable their separation in anaphase (Bhat et al., 1996) . To examine whether anaphase-bridge formation in RanBP2 hypomorphic MEFs might be due to Topo IIa insufficiency, we examined lysates from asynchronous MEF cultures of various RanBP2 genotypes for Topo IIa expression by immunoblotting. As shown in Figure 3A , Topo IIa expression levels were independent of RanBP2 status.
RanBP2
+/+ and RanBP2 À/H MEFs that were arrested in mitosis by nocodazole also contained similar amounts of Topo IIa ( Figure 3B 
RanBP2 Binds to Topo IIa in Mitosis
Because Topo IIa localization in mitosis is RanBP2 dependent, we suspected that the two proteins might form a complex. To investigate this, RanBP2 was immunoprecipitated from interphase and mitotic HeLa cell extracts and examined for Topo IIa coprecipitation. As shown in Figure 3E , about 4%-5% of the cellular Topo IIa pool coimmunoprecipitated with RanBP2 from mitotic extracts but not from G1 or G2 extracts. In the reverse experiment, RanBP2 immunoprecipitated with Topo IIa from mitotic extracts but again not from interphase extracts (data not shown). (Takahashi et al., 2006) . Studies in Xenopus egg extracts and human cells suggest that Topo IIa is also subjected to sumoylation in higher eukaryotes (Azuma et al., 2003 Mao et al., 2000) . Since RanBP2 is a nucleoporin with SUMO E3 ligase activity (Pichler et al., 2002) , we speculated that this activity might be required for accumulation of Topo IIa at inner centromeres and proper separation of sister chromatids. To test this hypothesis, we expressed influenza hemagglutinin (HA) epitope-tagged RanBP2(2553-2838), a 33 kDa fragment spanning the RanBP2 SUMO E3 ligase domain (Pichler et al., 2004) HA-RanBP2(1950 -2553 and HA-RanBP2(2839-3224), were also expressed in RanBP2 À/H cells as controls ( Figure 4A ). Western blotting for HA revealed that all RanBP2 fragments were expressed at similar levels ( Figure S6 ). Consistent with our earlier results, 28% of RanBP2 À/H MEFs expressing empty vector formed anaphase bridges ( Figure 4B (Azuma et al., 2003 , did not correct anaphase-bridge formation (Figures 4B and S6) .
Complementary immunostaining experiments with antibodies to Topo IIa and centromeres revealed that the expression of RanBP2 SUMO E3 ligase domain in RanBP2
À/H cells greatly improved the targeting of Topo IIa to inner centromeres of mitotic chromosomes ( Figures 4C and 4D ). MEFs and precipitated it with an antibody against HA from mitotic extracts. As shown in Figure 4E , Topo IIa indeed coimmunoprecipitated with HA-RanBP2(2553-2838) from these extracts. In contrast, Topo IIa failed to coimmunoprecipitate with HA-RanBP2(1950 -2553 and HA-RanBP2(2839-3224). Thus, the SUMO E3 ligase domain of RanBP2 is sufficient for complex formation with Topo IIa in vivo.
RanBP2 Promotes Sumoylation of Topo IIa In Vitro and In Vivo
Next, we used an in vitro sumoylation assay to address whether Topo IIa is a substrate for SUMO modification by RanBP2. We incubated full-length purified human Topo IIa with recombinant SUMO E1, Ubc9, His-HA-RanBP2(2553-2838), SUMO1, and ATP for 1 hr. Topo IIa sumoylation was then analyzed by immunoblotting for Topo IIa. As shown in Figure 5A , Topo IIa was efficiently sumoylated by His-HA-RanBP2(2553 -2838 . No such modification occurred in the absence of His-HA-RanBP2(2553-2838) or ATP, or when catalytic mutant His-HA-RanBP2(2553-2838)
L2651A,L2653A was used instead of His-HA-RanBP2(2553-2838). We found that Topo IIa was also efficiently sumoylated by His-HA-RanBP2(2553-2838) when SUMO1 was replaced by SUMO2 or SUMO3 ( Figure S7A ). Collectively, these data demonstrate that Topo IIa is a substrate of RanBP2 for SUMO modification in vitro.
If RanBP2 indeed functions to sumoylate Topo IIa in mitosis, one would expect mitotic RanBP2 À/H MEFs to have reduced levels of SUMO-conjugated Topo IIa. To test whether this is the case, we stably expressed HA-tagged SUMO1 in RanBP2 +/+ and RanBP2
À/H MEFs ( Figure 5B ), harvested mitotic cells by mitotic shake-off, and analyzed lysates prepared from these cells for the presence of SUMO-conjugated Topo IIa by western Figure 5C , SUMO-modified Topo IIa was detectable in RanBP2 +/+ lysates but not in RanBP2 À/H lysates.
As expected, SUMO-modified Topo IIa was not observed when RanBP2 +/+ MEFs were lysed in the absence of the isopeptidase inhibitor N-ethylmaleimide (NEM; see Figure S7B ). The observation that RanBP2 hypomorphism leads to decreased sumoylation of Topo IIa in mitosis suggests that Topo IIa is an in vivo substrate of RanBP2 during this cell-cycle stage.
To further test whether Topo IIa is the relevant target of RanBP2 SUMO E3 ligase activity in mitosis, we expressed a Topo IIa construct encoding a nonhydrolyzable SUMO1 in linear N-terminal fusion with Topo IIa-EGFP in RanBP2 À/H MEFs and determined its ability to restore Topo IIa localization and efficient separation of sister chromatids in these cells. SUMO1-Topo IIa-EGFP fusion protein indeed targeted with high efficiency to inner centromeres of RanBP2 hypomorphic MEFs in mitosis ( Figure 5D ) and caused a dramatic reduction in anaphase-bridge formation in these cells ( Figure 5E ). These data support the idea that the mitotic defects seen in RanBP2 hypomorphic cells are due to impaired SUMO modification of Topo IIa. Depletion of PIASy in Xenopus egg extracts or HeLa cells has been shown to inhibit Topo IIa targeting to inner centromeres and block chromosome segregation (Azuma et al., 2003 Diaz-Martinez et al., 2006) , suggesting that RanBP2 and PIASy E3 ligases might have overlapping functions in mitosis. To investigate this, we analyzed the subcellular localization of Topo IIa in MEFs derived from PIASy À/À mice (Roth et al., 2004) . As shown in Figure 5F , PIASy loss had no impact on Topo IIa targeting to inner centromeres in mitosis. MEFs from an independently generated PIASy À/À mouse strain yielded the same results (Wong et al., 2004) Figure 5H ). These data demonstrate that, at least in MEFs, RanBP2 rather than PIASy regulates accumulation of Topo IIa at inner centromeres and proper chromosome segregation.
RanBP2 Insufficient Mice Are Prone to Carcinogen-Induced and Spontaneous Tumors
As RanBP2 insufficiency leads to chromosome number instability, a condition that has been linked to cancer development, we sought to determine whether mice with reduced RanBP2 expression are prone to tumorigenesis. To this end, we performed a tumor bioassay with 7,12-dimethylbenz[a]anthracene (DMBA), a carcinogen that predisposes wild-type mice to lung tumors, skin tumors, and thymic lymphomas when applied to the skin (Serrano et al., 1996) (I) Proposed model for the role of RanBP2 in sister-chromosome separation. In mitosis, RanBP2 (in conjunction with Ubc9) binds to and sumoylates Topo IIa in the mitotic cytosol. This modification serves as a signal for Topo IIa targeting to inner centromeres, where it functions to decatenate sister centromeres, thus allowing for proper separation of sister chromosomes in anaphase. As SUMO-modified Topo IIa represents only a small fraction of the total Topo IIa pool ( Figure 5C ), SUMO conjugation may only be required for initial targeting of Topo IIa to centromeres but not for maintenance of centromeric localization.
( Figures 6A and 6B , and RanBP2 +/À mice ( Figure 6B ). Compared with RanBP2 +/+ mice, the skin tumor burden was 16-and 23-fold increased in RanBP2 H/H and RanBP2 À/H mice, respectively ( Figure 6C ). In RanBP2 +/À and RanBP2 +/H mice this increase was only 3-fold. At 5 months of age, the animals were sacrificed and their internal organs were screened for tumors. Lung tumors were identified in 58% of RanBP2 +/+ mice ( Figures 6D and 6E ).
Small increases in the incidence of lung tumorigenesis were observed in RanBP2 +/À and RanBP2 +/H mice, but they were not statistically significant. In contrast, the increases in lung tumor incidence were much larger in RanBP2 
RanBP2
À/H animals developing on average 17 and 14 tumors per mouse, respectively, compared to three or less in the other genotypes ( Figure 6F ). Furthermore, to determine if RanBP2 insufficiency promotes spontaneous tumorigenesis, cohorts of RanBP2
H/H , and RanBP2
À/H mice were established and monitored biweekly for signs of overt tumors or ill health for up to 2 years. Moribund animals were sacrificed and screened for tumors. Tumors were collected and embedded in paraffin for histopathology. RanBP2 À/H and RanBP2 H/H mice formed tumors with increased incidence and shorter latency than RanBP2 +/+ mice ( Figure 6G ).
Lung adenocarcinomas were the most prevalent tumor type in RanBP2 À/H and RanBP2 H/H mice ( Figures 6H and 6I ). Other frequently observed tumor types in these mice were hepatocellular carcinomas and sarcomas. Chromosome counts and interphase fluorescence in situ hybridization (FISH) using probes for chromosomes 4, 7, 9, and 12 demonstrated that tumors of all three types consistently displayed severe aneuploidy ( Figures  6J and S9) . Thus, when RanBP2 expression drops below a critical threshold level, mice become prone to spontaneous and carcinogen-induced tumorigenesis. Furthermore, these studies establish RanBP2 as a protein with tumor-suppressive activity and reveal a correlation between aneuploidy and tumorigenesis.
DISCUSSION
RanBP2 has been implicated in both nucleocytoplasmic transport and mitosis and is unique among nucleoporins in that it is a SUMO E3 ligase. However, the critical biological functions of RanBP2 and the in vivo targets of its ligase activity have been unknown. Progress in understanding the physiological functions of mammalian nucleoporins has been hampered by the fact that most loss-of-function mutations disrupt early embryogenesis so severely that the embryo dies. One way around this problem is to study hypomorphic mutant mice. Using this approach, we established a requirement for RanBP2 in maintenance of chromosome number stability and suppression of tumorigenesis. The observation that the mitotic phenotype caused by RanBP2 hypomorphism is reminiscent of Topo IIa inhibition led to the discovery that RanBP2 regulation of chromosome segregation fidelity is mediated, at least in part, by the sumoylation of Topo IIa in mitosis.
RanBP2
Sumoylates Topo IIa to Mediate Sister-Chromatid Separation Siz1p and Siz2p, two proteins that provide the major SUMO (Smt3p) E3 ligase activity in budding yeast, execute SUMO modification of Top2p in mitosis (Takahashi et al., 2006) . This modification seems to function as a signal for Top2p targeting to pericentromeric regions of mitotic chromosomes. Seven observations reported here suggest that, in mammals, RanBP2 catalyzes the SUMO modification of Topo IIa in mitosis to direct this protein to inner centromeres for accurate chromosome separation prior to anaphase onset ( Figure 5I ). First, catalytic inhibition of Topo IIa causes formation of chromatin bridges in anaphase due to incomplete DNA decatenation (Clarke et al., 1993) . Anaphase-bridge formation is the primary phenotype of RanBP2 hypomorphic cells. Second, the RanBP2 hypomorphic cells fail to accumulate Topo IIa at inner centromeres of mitotic chromosomes at high incidence. Third, ectopic expression of the RanBP2 SUMO E3 ligase domain in RanBP2 hypomorphic cells by itself is sufficient to restore proper localization of Topo IIa to inner centromeres and prevent anaphase-bridge formation. These corrective effects require SUMO conjugation, as they were not observed in RanBP2 hypomorphic cells expressing catalytic mutants of the RanBP2 E3 ligase domain. Unlike Topo IIa, the RanBP2 SUMO E3 ligase domain and full-length RanBP2 do not concentrate at inner centromeres of mitotic chromosomes, suggesting that Topo IIa is sumoylated by RanBP2 in the mitotic cytosol and, from there, translocates to inner centromeres of duplicated chromosomes without RanBP2 ( Figure 5I ). Fourth, RanBP2 forms a complex with Topo IIa specifically in mitosis. Importantly, the abundance of RanBP2-Topo IIa complexes is substantially reduced in RanBP2 hypomorphic cells. Fifth, the RanBP2 SUMO E3 ligase domain, which is sufficient for Topo IIa binding, efficiently catalyzes SUMO conjugation of Topo IIa in an in vitro assay using recombinant proteins. We show that Topo IIa can be modified by all three SUMO species in this assay. Sixth, RanBP2 hypomorphic cells have substantially lower levels of SUMO-modified Topo IIa than cells expressing a full complement of RanBP2. Furthermore, ectopic expression of the RanBP2 SUMO E3 ligase domain in RanBP2 hypomorphic cells is sufficient to restore SUMO conjugation of Topo IIa in mitosis. Seventh, ectopically expressed SUMO1-Topo IIa fusion protein corrects both Topo IIa mislocalization and anaphase-bridge formation in RanBP2 hypomorphic MEFs. As expression of the catalytically active SUMO E3 ligase domain has similar corrective effects in these cells, it is reasonable to conclude that Topo IIa is the relevant substrate of RanBP2 in mitosis.
Previous studies in Xenopus egg extracts have implicated PIASy in the sumoylation of Topo IIa (Azuma et al., 2003 . This combined with the observation that depletion of PIASy from these extracts results in metaphase arrest led to speculation that sumoylation of Topo IIa is essential for sister-chromatid separation in mitosis. The observation that siRNA-mediated depletion of PIASy from HeLa cells interferes with targeting of Topo IIa and blocks separation of duplicated chromosomes further supported this idea (Diaz-Martinez et al., 2006) . However, here we demonstrate that Topo IIa sumoylation, Topo IIa accumulation at inner centromeres, and proper separation of sister chromosomes are unperturbed in PIASy À/À MEFs. Consistent with this, PIASy À/À mice are viable, fertile, and devoid of any overt phenotypes (Roth et al., 2004; Wong et al., 2004) . Furthermore, PIASy overexpression was found to be unable to correct Topo IIa mislocalization and chromosome missegregation in RanBP2 hypomorphic MEFs. One interpretation is that the role of RanBP2 and PIASy in Topo IIa sumoylation is species, cell type, and/or transformation status dependent. It is also possible that off-target effects of siRNA oligos drive aberrant Topo IIa localization and chromosome segregation in the PIASy-depleted HeLa cells. Furthermore, it is unknown whether depletion of PIASy in HeLa cells correlates with impaired SUMO modification of Topo IIa.
RanBP2 in Chromosomal Instability and Tumorigenesis
Our finding that RanBP2 hypomorphic mice are highly susceptible to carcinogen-induced tumors and prone to various spontaneous tumors reveals a novel and important role for RanBP2 in suppression of tumorigenesis. What could be the tumor-suppressive function(s) of RanBP2? Given that RanBP2 hypomorphism induces aneuploidy and that the incidence of aneuploidy is high in human cancers, it is tempting to speculate that RanBP2 exerts its tumor-suppressive effect by ensuring accurate segregation of duplicated chromosomes in mitosis. The finding that aneuploidy is high in tumors from RanBP2 hypomorphic mice supports this notion. Yet, whether aneuploidy is causally implicated in cancer development has been a subject of intense investigation and debate. Recent studies of mutant mouse strains with defects in mitotic checkpoint genes that increase the incidence of missegregation of whole chromosomes suggest that aneuploidy indeed has the ability to promote tumorigenesis (Weaver and Cleveland, 2006) . Structural chromosome defects have also been implicated in tumor development. Despite having high rates of chromatin-bridge formation, RanBP2 hypomorphic MEFs showed no evidence of increased gross chromosomal aberrations. However, this does not exclude the possibility that structural chromosome damage from improper decatenation contributes to tumor development in RanBP2 mutant mice. For instance, it is possible that transformed cells may be more resistant to cell death induced by structural damage than nontransformed cells. Although RanBP2 is a well-established component of the mammalian NPC, cells that are hypomorphic for this protein displayed no overt defects in NLS-dependent protein import, NES-dependent protein export, or mRNA export. These findings suggest that tumor development in RanBP2 hypomorphic mice is unlikely due to impairments in some of the major transport pathways. However, it cannot be excluded that specific NLS-or NES-containing proteins that are important for controlled cell proliferation or induction of apoptosis are expressed at inappropriate levels or unable to reach their intracellular sites of action in RanBP2 hypomorphic mice. Moreover, only those transport pathways that were functionally impaired by RanBP2 depletion in HeLa cells were included in our analysis (Bernad et al., 2004; Hutten and Kehlenbach, 2006) . Thus, it is possible that certain transport pathways are not optimally functioning in RanBP2 hypomorphic cells.
To explore whether RanBP2 might have a role in human cancer, we compared the relative expression of RanBP2 in normal tissue versus tumors using human gene expression data from the Oncomine database (http://www.oncomine.com). RanBP2 hypomorphic mice are particularly sensitive to spontaneous and carcinogen-induced lung tumors. Consistent with these data, two independent studies revealed that RanBP2 transcript levels are substantially reduced in human non-small cell lung cancers (Beer et al., 2002; Garber et al., 2001) . These findings, along with data showing that RanBP2 expression is frequently downregulated in human lung cancer cell lines and primary lung tumor samples (D. Baker and J.M.v.D., unpublished data), suggest that RanBP2 downregulation is a frequent event in human lung tumorigenesis.
EXPERIMENTAL PROCEDURES
Generation of Hypomorphic and Knockout Mice and Tumor Susceptibility Studies
The gene targeting procedure used to generate the hypomorphic RanBP2 allele (H) was as previously described (Dawlaty and van Deursen, 2006) . Correctly targeted ES cell clones were injected into blastocysts and RanBP2 +/H offspring were obtained from the resulting chimeras through standard procedures. RanBP2 +/À mice were established by Cre-mediated excision of RanBP2 exon 3 in the female germline by the use of MMTV-Cre transgenic mice (this excision causes out-of-frame fusion of exons 2 and 4). All mice were maintained on a 129Sv/E 3 C57BL/6 genetic background. Mice in tumor susceptibility studies were monitored daily. Moribund mice were killed and their major organs screened for overt tumors. Tumors were processed for histopathology by standard procedures. Prism software was used for the generation of tumorfree survival curves and for statistical analyses. DMBA treatment was as described (Serrano et al., 1996) .
Western Blotting and Coimmunoprecipitation
Western blot analyses and coimmunoprecipitations were essentially done as described (Kasper et al., 1999) . Lysis buffer for detection of SUMO-modified Topo IIa by western blotting consisted of 50 mM Tris HCl (pH 7.5), 150 mM NaCl, 0.1% NP40, 0.5% SDS, protease inhibitor cocktail (Roche, Cat. #11-836-170-001), and 20 mM NEM. Samples were kept on ice for 15 min and vortexed at $2 min intervals and then boiled in Laemmli buffer. Antibodies were rabbit anti-hRanBP2(2500-3224) and rabbit anti-hRanBP2(2550-2837) (Joseph et al., 2004) ; rabbit anti-Topo IIa (Topogen); mouse anti-b-actin (AC-151, Sigma); rat anti-HA (3F10; Roche); and mouse anti-phosphohistone H3 (Ser10) (Upstate).
Indirect Immunofluorescence and Live-Cell Imaging
MEFs were cultured on 10-well glass slides for 24 hr, arrested in prometaphase with 100 mM monastrol for 3 hr, and fixed with 3% paraformaldehyde in PBS for 12 min. Antibody incubations were as described (Kasper et al., 1999) . Antibodies were rabbit anti-Topo IIa (Topogen); human anti-centromeric antibody (Antibodies Incorporated); rabbit anti-Mad1 (Dr. T. Yen); and rabbit anti-Cenp-E (Dr. D. Cleveland). Live-cell imaging was performed as described (Jeganathan et al., 2005) .
In Vitro Sumoylation Assays Sumoylation reactions were carried out in a total volume of 20 ml. Reactions contained 50 mM HEPES (pH 8), 100 mM NaCl, 1 mM DTT, 1 mM Mg-ATP, 50 nM E1 (110 ng), 25 mM SUMO1, 2, or 3 (5 mg), 125 nM Ubc9 (50 ng), 100 ng recombinant His-HA-RanBP2(2553-2838) or His-HA-RanBP2 (2553-2838) L2651A,L2653A
, and 20 ng of purified full-length Topo IIa (Topogen). Reactions were performed at 37 C for 1 hr, stopped with equal volume of 23
Laemmli buffer, resolved by SDS-PAGE on 5% Tris-HCl gels, and analyzed by immunoblotting for Topo IIa. Recombinant E1, Ubc9, and SUMO1-3 were from Boston Biochem (SUMO1 conjugation kit; Cat. #K-710). To produce recombinant RanBP2 His-HA-RanBP2(2553-2838) and His-HA-RanBP2 (2553-2838) L2651A,L2653A
, their corresponding cDNA constructs were cloned into BamH1 and Xho1 sites of pET28a(+) (Novagen). Proteins tagged with His were expressed in BL21 (DE3) bacteria at 15 C and purified from bacterial lysates with Ni 2+ agarose.
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